Company Analysis

Repligen Corporation (RGEN)

Nasdaq: RGEN · Biological Products, (No Diagnostic Substances) · Waltham, MA · filing with the SEC since 1995
Grade5.4
◀ Past 6.3● Present 6.4▶ Future 4.1

The company now

Repligen Corporation is classed by the SEC under Biological Products, (No Diagnostic Substances) (industry code 2836), based in Waltham, MA. In its latest annual figures on file, for the fiscal year ended 2025-12-31, it reported revenue of $738 million and a profit of $49 million (its filed statements).

From its filings and filed figures; the desk's account of it is not written yet.

Where the revenue comes from

fiscal 2025, as filed

Revenue by product, fiscal 2025

ProductFiscal 2025Fiscal 2024Share of revenue
Filtration Products$403M$373M54.6%
Chromatography Products$153M$123M20.7%
Proteins Products$97.4M$74.4M13.2%
Process Analytics Products$81.2M$59.3M11.0%
Other Products$3.3M$4.7Munder 1%
Royalty$296,000$261,000under 1%

As tagged in its annual report (Form 10-K, filed Feb 26, 2026 ↗), read from the SEC's financial statement data sets. The year before is the figure the record holds for the prior fiscal year.

The desk's written account of this company, its Past, Present and Future, is not on file yet.

How the company works

The desk has not read this company's annual report yet.

The record in brief

The desk has not written this company's report yet.

SI Assistanton RGEN · research, not advice